Iron Deficiency Anemia - Pipeline Review, H2 2018

  • ID: 4592455
  • Report
  • 79 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Akebia Therapeutics Inc
  • Galenica Ltd
  • Novartis AG
  • Panion & Bf Biotech Inc
  • Pharmacosmos AS
  • Rockwell Medical Inc
  • MORE
Iron Deficiency Anemia - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Iron Deficiency Anemia - Pipeline Review, H2 2018, provides an overview of the Iron Deficiency Anemia (Hematological Disorders) pipeline landscape.

Anemia is a condition in which the body does not have enough healthy red blood cells. Iron helps make red blood cells. When body does not have enough iron, it will make fewer red blood cells or red blood cells that are too small. This is called iron deficiency anemia. Symptoms include feeling grumpy, headaches and problems concentrating or thinking. Treatment includes iron supplements and eating iron-rich foods.

Report Highlights:

This latest pipeline guide Iron Deficiency Anemia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Iron Deficiency Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Iron Deficiency Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Iron Deficiency Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 3, 3, 2 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Iron Deficiency Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Iron Deficiency Anemia (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Iron Deficiency Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Iron Deficiency Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Iron Deficiency Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Iron Deficiency Anemia (Hematological Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Iron Deficiency Anemia (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Iron Deficiency Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Akebia Therapeutics Inc
  • Galenica Ltd
  • Novartis AG
  • Panion & Bf Biotech Inc
  • Pharmacosmos AS
  • Rockwell Medical Inc
  • MORE
Introduction

Report Coverage

Iron Deficiency Anemia - Overview

Iron Deficiency Anemia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Iron Deficiency Anemia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Iron Deficiency Anemia - Companies Involved in Therapeutics Development

Akebia Therapeutics Inc

Galenica Ltd

Novartis AG

Panion & Bf Biotech Inc

Pharmacosmos AS

Pieris Pharmaceuticals Inc

Rockwell Medical Inc

Shield Therapeutics Plc

Iron Deficiency Anemia - Drug Profiles

AKB-5343 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSJ-137 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Replace Iron for Iron Deficiency Anemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric carboxymaltose - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric maltol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric pyrophosphate citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hinokitiol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

iron isomaltoside - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSC-8679 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Activate Erythroferrone for Iron Deficiency Anemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polyglucoferron - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRS-080 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PT-30 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Iron Deficiency Anemia - Dormant Projects

Iron Deficiency Anemia - Product Development Milestones

Featured News & Press Releases

Jun 28, 2018: Shield Reports Recently Presented Supportive Data from Real-world Clinical use of Feraccru (Ferric Maltol)

Jun 14, 2018: Shield reports positive top-line results from its AEGIS-PAED PK Pediatric Phase I Pharmacokinetics study of Feraccru (Ferric Maltol) in subjects with iron deficiency

May 02, 2018: Rockwell Medical Announces Triferic Presentations at the 2018 International Congress on Peritoneal Dialysis

Apr 06, 2018: Shield Therapeutics Announces Results of its Pre-Submission Meeting with FDA

Mar 27, 2018: Shield receives EU Commission approval for the broadening of the indication for Feraccru (Ferric Maltol) to the treatment of Iron Deficiency in adults

Mar 20, 2018: Rockwell Medical Announces Triferic Presentations at the 2018 Asia Pacific Congress of Nephrology

Mar 16, 2018: Shield Therapeutics: Update on the AEGIS-CKD study

Feb 28, 2018: Rockwell Medical Announces Triferic Presentations at the 2018 Annual Dialysis Conference

Feb 28, 2018: Iron4u Completed Clinical Phase II and Granted PIP by EMA for New Human IV Iron

Feb 23, 2018: Shield Therapeutics receives CHMP positive opinion for Feraccru (Ferric Maltol) for the treatment of Iron Deficiency in adults

Feb 22, 2018: Shield Therapeutics Provides Update on Feraccru

Feb 05, 2018: Shield reports top-line results from pivotal Phase III study of Feraccru (Ferric Maltol) in the treatment of IDA in patients with CKD

Nov 07, 2017: U.S. FDA Approves Auryxia (ferric citrate) Tablets as a Treatment for People with Iron Deficiency Anemia and Chronic Kidney Disease, Not on Dialysis

Nov 02, 2017: Keryx Biopharmaceuticals Announces Presentation of Post-Hoc Data From Phase 3 Study of Auryxia (Ferric Citrate) in Adults With Iron Deficiency Anemia and Non-dialysis Dependent Chronic Kidney Disease

Oct 30, 2017: Rockwell Medical Announces Two Triferic Poster Presentations at American Society of Nephrology Kidney Week 2017 Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Iron Deficiency Anemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Iron Deficiency Anemia - Pipeline by Akebia Therapeutics Inc, H2 2018

Iron Deficiency Anemia - Pipeline by Galenica Ltd, H2 2018

Iron Deficiency Anemia - Pipeline by Novartis AG, H2 2018

Iron Deficiency Anemia - Pipeline by Panion & Bf Biotech Inc, H2 2018

Iron Deficiency Anemia - Pipeline by Pharmacosmos AS, H2 2018

Iron Deficiency Anemia - Pipeline by Pieris Pharmaceuticals Inc, H2 2018

Iron Deficiency Anemia - Pipeline by Rockwell Medical Inc, H2 2018

Iron Deficiency Anemia - Pipeline by Shield Therapeutics Plc, H2 2018

Iron Deficiency Anemia - Dormant Projects, H2 2018

List of Figures

Number of Products under Development for Iron Deficiency Anemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Akebia Therapeutics Inc
  • Galenica Ltd
  • Novartis AG
  • Panion & Bf Biotech Inc
  • Pharmacosmos AS
  • Pieris Pharmaceuticals Inc
  • Rockwell Medical Inc
  • Shield Therapeutics Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll